In the market for Total Joint Replacement, companies continue to innovate with assistive technologies and new implants and instruments to advance clinical outcomes and increase efficiency of care. From new hip products optimized for the direct anterior approach to cementless knee solutions, companies are focusing on technologies that provide optimal outcomes whether surgeries are performed in a hospital, hospital outpatient or ASC setting. The following is a sample of SmartTRAK's recent Total Joints news and developments from around the world, compiled, curated and posted in real time by the expert analysts at SmartTRAK.

We constantly monitor the worldwide MedTech industry, sifting through the noise to present to our subscribers the most relevant international news, trends, new products, patents, financial data and competitor developments in the global Life Sciences industry. If you'd like to receive these expert insights daily, Contact Us to learn more. Our users think it's the perfect way to start their day.

New Products:

• JNJ/DePuy Synthes*
  

  JNJ/DePuy Synthes did not discuss its new EMPHASYS hip implants during its Q322 earnings call. However, SmartTRAK would not be surprised to see the Company introduce the system at AAHKS 2022 with the EMPHASYS Cup* recently receiving 510(k) clearance to round out the platform.

• Exactech*

  Exactech announced the successful first surgeries and limited launch of the Novel Total Hip Arthroplasty System with the Spartan Stem* and Logical Cup* with full commercial US launch planned for H123. Exactech is a distributor of the implants supplied by Signature Orthopaedics*.

Among the many topics covered in detail in our comprehensive Q222 Extremities Market Recap* are:

John Uribe, MD, discusses inset glenoid technology and the future of shoulder replacement

John Uribe, MD, discusses his most recent research and experience with inset glenoids and how inset glenoids could influence the practice of shoulder replacement surgery. Dr. Uribe is a dual board-certified orthopedic surgeon with Baptist Health Group South Florida specializing in sports medicine, arthroscopic surgery and minimally invasive surgical procedures for degenerative knee, shoulder and elbow conditions. He is also the Chair of the Herbert Wertheim College of Medicine, Coral Gables, FL and the team physician for the Florida Panthers hockey team and the Miami Dolphins football team.

Dr. Uribe authored a study published in JSES International reporting results from 39 patients with advanced shoulder arthritis having anatomic shoulder replacement with the OVOMotion Shoulder Arthroplasty System from Anika, a stemless shoulder with an inlay glenoid component. The study demonstrated that treatment with inlay total shoulder arthroplasty resulted in significant functional improvement, pain relief and patient satisfaction at a mean follow-up of 41 months.

To find out more, including Dr. Uribe’s thoughts on the benefits of inlay glenoids vs onlay; the potential acceptance of inlay technology; trends such as the shift to reverse shoulders, site-of-care; and what’s next, click on the video below to listen to the recorded interview (17:36 min). A link to download a complete transcript of the interview is also provided below.

Despite stronger headwinds from slowing elective procedures, supply chain challenges and unfavorable foreign exchange rates, most total joint companies saw positive growth in Q222.

The WW Total Joints Market grew in Q222 despite slowing sequential growth compared to Q122’s growth. A slowdown in elective procedures late in the quarter along with continued supply chain challenges and the effect of foreign exchange rates resulted in stronger headwinds. SmartTRAK notes that several companies reported the carryover of these headwinds into Q3 that could dampen market recovery through year-end.

Among the many topics covered in detail in our comprehensive Q222 Total Joints Market Recap* are:

The return of elective procedure volumes, new product offerings and a busy first quarter of acquisitions all supported healthy growth for the Extremities Market

While growth drivers varied for specific companies in Q122, the return of elective procedure volumes helped drive double-digit growth for several market players. Stryker*, the Extremities Market leader, benefited from the return of elective procedures in the US. Its US Foot & Ankle and Upper Extremities business segments contributed to the Company’s US Trauma & Extremities growth during the quarter. Stryker also noted during its earnings call that ...

Among the many topics covered in detail in our comprehensive Q122 Extremities Market Recap* are:

Procedure volume recovery is not the only trend on SmartTRAK’s radar

Procedure volume recovery continues to be a trend on everyone’s radar from industry execs to healthcare providers. In Q122, the Knee Replacement Market in the US seemed to experience a much stronger recovery than Hips based on YoY growth rates, according to SmartTRAK Financial Dashboard. However, Knees faced a much easier YoY comp as more knee procedures were postponed in Q121 compared to hips due to their more elective nature. Putting this into perspective, US Hip Market growth along with Knees reinforced the feeling that 2022 procedures will be closer to “normal” as the Total Joints Market recovers from the downsizing caused by COVID.  And, as the industry’s bandwidth for focusing on the pandemic decreases, the emphasis on other trends grows.

Among the many topics covered in detail in our comprehensive Q122 Total Joints Market Recap* are:

From economics to the ASC shift, SmartTRAK looks at the trends affecting the Total Joints Market

The start of the new year did not play out as so many of us had hoped. Heading into 2022, the next COVID surge reared its ugly head with the Omicron variant storming through countries around the globe. Healthcare facilities once again postponed elective procedures due to capacity issues and/or staff or patients being diagnosed with COVID. Overall inflation rose to a level that hasn’t been seen since the early 1980s. Looking ahead, is there a silver lining in this dark cloud? SmartTRAK believes the forecast is not all doom and gloom. Let’s look at some of the trends affecting the climate of the Total Joints market.

(Continue reading to find out how to receive FREE SmartTRAK DAILY UPDATES)

Dr. Mark Figgie, Hospital for Special Surgery, and Nick Deeter, Founder & CEO WishBone Medical discuss their journey to develop a pediatric-specific hip replacement system in an interview with SmartTRAK

Dr. Mark P. Figgie, Chief of Surgical Arthritis Service at Hospital for Special Surgery (HSS) in New York City, and Nick Deeter, Founder and CEO of WishBone Medical discuss their collaboration on the development of the first off-the-shelf hip replacement system for pediatric patients in an interview with   SmartTRAK. Dr. Figgie shares how his 30-year experience with complex joint replacements, many in juvenile patients, led to his collaboration with WishBone medical to create a hip system specifically tailored for pediatric and young adult patients.

To find out more, including the indications for a pediatric hip replacement, the global market implications, and the next steps Dr. Figgie and WishBone will be taking to bring this hip system to the market, click on the video below to listen to the recorded interview (17:53 min). A link to download the complete transcript of the interview is also provided below.

New products and signs of procedural recovery lighten the mood at AAOS 2022

The mood at the American Academy of Orthopedic Surgeons (AAOS) 2022 Annual Meeting was upbeat despite scaled-back attendance and exhibit space. Surgeons and exhibitors alike were excited to get back to in-person discussions about issues in orthopedics, new products hitting the market and the potential for recovery from the impact of COVID. While at the meeting, SmartTRAK met with industry professionals from clinicians to company representatives identifying key takeaways from market drivers and limiters to new product introductions.

(Continue reading to find out how to receive FREE SmartTRAK DAILY UPDATES)

Covid-19 Delta surges shatter dreams of strong Q321 market recovery

Surges in COVID-19 Delta cases shattered any dreams of a strong Q321 Total Joints market recovery. Postponement of elective procedures in various areas of the US again negatively impacted Companies pushing out hopes for a return to normal into 2022. In addition to procedure recovery challenges, China’s Volume-Based Procurement program that aims to reduce implant pricing may headwind to the WW Total Joints market in the coming year.

Among the many topics covered in detail in our comprehensive Q321 Total Joints Market Recap* are:

• Complete Q321 Total Joints Market Overview and Highlights
• SmartTRAK's Expert Analysis and Insights
• Total Joints News including Revenues, Data, Charts and Shares
• US Market Growth Comparison Q321 vs Q319
• New Products Hitting the Stage
• Q321 Regulatory Highlights